BC Innovations | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
BC Innovations | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); pyruvate dehydrogenase kinase 1 (PDK1); serum/glucocorticoid regulated kinase 1 (SGK1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting PDK1 or SGK1 could help treat PI3Kα inhibitor-resistant breast cancer. In breast cancer patients, high tumor expression of SGK1 correlated with resistance...
BC Innovations | Dec 19, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Staurosporine analogs (staralogs) with improved selectivity toward analog-sensitive kinases Staralogs could expand approaches to study kinase function using analog-sensitive kinase variants. Kinase variants with genetically...
BC Innovations | Jun 13, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Pyruvate dehydrogenase kinase 1 (PDK1) Cell culture and mouse studies suggest inhibiting PDK1 could help treat melanoma. In a mouse...
BC Innovations | Mar 21, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer K-Ras; 3-phosphoinositide-dependent protein kinase-1 (PDPK1) Mouse studies suggest inhibiting PDPK1 could help prevent mutant K-Ras-driven pancreatic ductal adenocarcinomas (PDACs)....
BC Week In Review | Sep 7, 2009
Clinical News

AR-12: Phase I started

Arno began an open-label, dose-escalation, U.S. and European Phase I trial to evaluate oral AR-12 given for 28 consecutive days in up to 50 patients. Arno Therapeutics Inc. (OTCBB:ARNI), Fairfield, N.J.   Product: AR-12 (formerly...
BC Week In Review | Apr 24, 1995
Company News

Millennium other research news

The Cambridge, Mass., company and collaborators published in Cell their complete sequencing of the gene. Earlier this month, Integrated Genetics (IGLI, Framingham, Mass.) also announced full identification of the gene. Several similar genes are located...
BC Week In Review | Apr 3, 1995
Company News

Integrated Genetics Inc. other research news

IGLI (Framingham, Mass.) announced full identification of the gene for polycystic kidney disease, with the next step to be a search for mutations causing the genetic defect. The gene was identified by genomic sequencing. Several...
Items per page:
1 - 8 of 8